Yoshiya Yamauchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoshiya Yamauchi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Takao Itoi
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan
2 shared publications - Akira Madarame
Affiliation Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan
1 shared publication Atsushi Sofuni
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan
1 shared publication- Atsushi Sofuni
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan
1 shared publication - Fumito Yamanishi
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan
1 shared publication - Haruki Kaizuka
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 695
Salivary Polyamine Ratios as Candidate Biomarkers for Gastric Cancer: A Proof-of-Concept Case–Control Study
Background/Objectives: Gastric cancer (GC) is one of the most prevalent malignancies worldwide, highlighting the need for minimally invasive and highly accurate screening methods for its early detection. We evaluated the utility of salivary polyamine-based metabolomic analysis for distinguishing individuals with GC from those without GC. Methods: A total of 53 patients with GC and 37 non-GC controls were included. Participants were recruited from individuals who underwent upper gastrointestinal endoscopy at Tokyo Medical University Hospital between March 2020 and May 2025 and provided saliva samples on the same day. Participants with factors known to affect polyamine levels were excluded. Salivary metabolites quantified by liquid chromatography–mass spectrometry were statistically compared between groups. Acetylated-to-non-acetylated polyamine ratios were used as features to construct a logistic regression-based machine learning model, and discriminative performance was evaluated using receiver operating characteristic analysis. Results: The GC group showed significantly higher concentrations of salivary metabolites. Among individual polyamines, N1-acetylspermine demonstrated the highest discriminative ability (AUC = 0.845). When acetylated-to-non-acetylated polyamine ratios were analyzed, significant differences between groups were observed for N1,N8-diacetylspermidine/spermidine and N1-acetylspermine/spermine. A logistic regression model constructed using six such ratios achieved strong predictive performance in the test dataset (AUC = 0.807), with a sensitivity of 68.8% and a specificity of 72.7%. Conclusions: Our results demonstrate that salivary polyamine analysis, particularly using acetylation ratios, enables accurate and minimally invasive discriminative ability of GC and represents a promising adjunctive tool for GC screening.
- 22 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 695
Open AccessSalivary Polyamine Ratios as Candidate Biomarkers for Gastric Cancer: A Proof-of-Concept Case–Control Study
Background/Objectives: Gastric cancer (GC) is one of the most prevalent malignancies worldwide, highlighting the need for minimally invasive and highly accurate screening methods for its early detection. We evaluated the utility of salivary polyamine-based metabolomic analysis for distinguishing individuals with GC from those without GC. Methods: A total of 53 patients with GC and 37 non-GC controls were included. Participants were recruited from individuals who underwent upper gastrointestinal endoscopy at Tokyo Medical University Hospital between March 2020 and May 2025 and provided saliva samples on the same day. Participants with factors known to affect polyamine levels were excluded. Salivary metabolites quantified by liquid chromatography–mass spectrometry were statistically compared between groups. Acetylated-to-non-acetylated polyamine ratios were used as features to construct a logistic regression-based machine learning model, and discriminative performance was evaluated using receiver operating characteristic analysis. Results: The GC group showed significantly higher concentrations of salivary metabolites. Among individual polyamines, N1-acetylspermine demonstrated the highest discriminative ability (AUC = 0.845). When acetylated-to-non-acetylated polyamine ratios were analyzed, significant differences between groups were observed for N1,N8-diacetylspermidine/spermidine and N1-acetylspermine/spermine. A logistic regression model constructed using six such ratios achieved strong predictive performance in the test dataset (AUC = 0.807), with a sensitivity of 68.8% and a specificity of 72.7%. Conclusions: Our results demonstrate that salivary polyamine analysis, particularly using acetylation ratios, enables accurate and minimally invasive discriminative ability of GC and represents a promising adjunctive tool for GC screening.
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 174
Prognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a single-center retrospective cohort study
Background: Prognostic stratification at the initiation of chemotherapy is clinically important in patients with metastatic or recurrent unresectable pancreatic cancer. The lactate dehydrogenase-to-albumin ratio (LAR) is an objective blood-based index that combines tumor-associated activities with systemic conditions of the host; however, evidence of its usefulness as a prognostic index in patients receiving first-line gemcitabine plus nab-paclitaxel (GnP) remains limited. In this study, we evaluated the prognostic value of baseline LAR in these patients. Methods: This single-center retrospective cohort study included consecutive patients with metastatic or recurrent unresectable pancreatic cancer who underwent first-line GnP between 2015 and 2024. Baseline LAR was calculated from laboratory data obtained within 7 days before treatment initiation, and neutrophil-to-lymphocyte ratio (NLR) was evaluated as a comparative inflammatory marker. The primary analysis evaluated the association between baseline LAR and overall survival (OS) using prespecified multivariable Cox proportional hazards models. The functional form of LAR was examined using restricted cubic splines (RCS). Kaplan-Meier curves were then presented to visualize risk stratification by combining Eastern Cooperative Oncology Group performance status (ECOG PS) with LAR. The incremental prognostic performance beyond the base clinical model was evaluated using model fit and discrimination metrics, with bootstrap internal validation. Results: The final analytic cohort comprised 205 patients (median age, 67 years; 63.9% men). The median baseline LAR was 4.94. In the prespecified multivariable model, ECOG PS and LAR were independently associated with OS [PS 2 vs. 0: hazard ratio (HR), 2.38; 95% confidence interval (CI), 1.28–4.42; LAR per 1-standard deviation (SD) increase: HR, 1.29; 95% CI, 1.09–1.52]. RCS analysis demonstrated a significant overall association without evidence of nonlinearity (overall P=0.03; nonlinear P=0.71). Kaplan-Meier curves for four risk groups defined by PS (0–1 vs. 2) and LAR (below vs. at/above the median) showed significant separation (log-rank PConclusions: Baseline LAR was independently associated with OS after adjustment for ECOG PS in patients receiving first-line GnP. Therefore, PS combined with LAR may enable simple prognostic stratification at treatment initiation, pending confirmation in future external validation cohorts.
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 174
Open AccessPrognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a single-center retrospective cohort study
Background: Prognostic stratification at the initiation of chemotherapy is clinically important in patients with metastatic or recurrent unresectable pancreatic cancer. The lactate dehydrogenase-to-albumin ratio (LAR) is an objective blood-based index that combines tumor-associated activities with systemic conditions of the host; however, evidence of its usefulness as a prognostic index in patients receiving first-line gemcitabine plus nab-paclitaxel (GnP) remains limited. In this study, we evaluated the prognostic value of baseline LAR in these patients. Methods: This single-center retrospective cohort study included consecutive patients with metastatic or recurrent unresectable pancreatic cancer who underwent first-line GnP between 2015 and 2024. Baseline LAR was calculated from laboratory data obtained within 7 days before treatment initiation, and neutrophil-to-lymphocyte ratio (NLR) was evaluated as a comparative inflammatory marker. The primary analysis evaluated the association between baseline LAR and overall survival (OS) using prespecified multivariable Cox proportional hazards models. The functional form of LAR was examined using restricted cubic splines (RCS). Kaplan-Meier curves were then presented to visualize risk stratification by combining Eastern Cooperative Oncology Group performance status (ECOG PS) with LAR. The incremental prognostic performance beyond the base clinical model was evaluated using model fit and discrimination metrics, with bootstrap internal validation. Results: The final analytic cohort comprised 205 patients (median age, 67 years; 63.9% men). The median baseline LAR was 4.94. In the prespecified multivariable model, ECOG PS and LAR were independently associated with OS [PS 2 vs. 0: hazard ratio (HR), 2.38; 95% confidence interval (CI), 1.28–4.42; LAR per 1-standard deviation (SD) increase: HR, 1.29; 95% CI, 1.09–1.52]. RCS analysis demonstrated a significant overall association without evidence of nonlinearity (overall P=0.03; nonlinear P=0.71). Kaplan-Meier curves for four risk groups defined by PS (0–1 vs. 2) and LAR (below vs. at/above the median) showed significant separation (log-rank PConclusions: Baseline LAR was independently associated with OS after adjustment for ECOG PS in patients receiving first-line GnP. Therefore, PS combined with LAR may enable simple prognostic stratification at treatment initiation, pending confirmation in future external validation cohorts.
- Open Access
Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center
Background: Biliary tract cancers (BTCs), including gallbladder and bile duct cancers, have a poor prognosis. Recent advances in chemotherapy, such as using targeted drugs for specific gene mutations, have improved outcomes. Gemcitabine plus cisplatin chemotherapy has been the standard of care for the primary treatment of BTCs, but secondary treatment had not been established until recently. In recent years, durvalumab plus gemcitabine and cisplatin (GCD) chemotherapy is emerging as a promising regimen, although more evidence is needed for its effectiveness. Methods: This retrospective single-center study involved 44 patients receiving GCD treatment between January 2023 and March 2024 with a median follow-up of 10 months. Outcomes focused on overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Results: The overall response rate (ORR) was 23%, and the disease control rate (DCR) was 82%. The overall median OS and PFS were 15.3 and 8.0 months, respectively, with patients receiving primary chemotherapy experiencing longer survival compared to a control group. Patients who did not undergo bile duct drainage had statistically different better OS and PFS. Grade 3 or higher AEs occurred in 54.5% of patients, with neutropenia and biliary infections being common. Conclusions: GCD chemotherapy shows potential as an effective treatment for BTCs. The favorable treatment outcome was the response rate, particularly in primary therapy or those cases with no metastasis. Bile duct management is crucial for improving patient outcomes. GCD chemotherapy has a high response rate, PFS, and OS compared to other forms of chemotherapy.
Open AccessInitial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center
Background: Biliary tract cancers (BTCs), including gallbladder and bile duct cancers, have a poor prognosis. Recent advances in chemotherapy, such as using targeted drugs for specific gene mutations, have improved outcomes. Gemcitabine plus cisplatin chemotherapy has been the standard of care for the primary treatment of BTCs, but secondary treatment had not been established until recently. In recent years, durvalumab plus gemcitabine and cisplatin (GCD) chemotherapy is emerging as a promising regimen, although more evidence is needed for its effectiveness. Methods: This retrospective single-center study involved 44 patients receiving GCD treatment between January 2023 and March 2024 with a median follow-up of 10 months. Outcomes focused on overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Results: The overall response rate (ORR) was 23%, and the disease control rate (DCR) was 82%. The overall median OS and PFS were 15.3 and 8.0 months, respectively, with patients receiving primary chemotherapy experiencing longer survival compared to a control group. Patients who did not undergo bile duct drainage had statistically different better OS and PFS. Grade 3 or higher AEs occurred in 54.5% of patients, with neutropenia and biliary infections being common. Conclusions: GCD chemotherapy shows potential as an effective treatment for BTCs. The favorable treatment outcome was the response rate, particularly in primary therapy or those cases with no metastasis. Bile duct management is crucial for improving patient outcomes. GCD chemotherapy has a high response rate, PFS, and OS compared to other forms of chemotherapy.